Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human insulin injection (short-acting) vs Actrapid in type 1 and type 2 diabetes
CTR20150293Phase 3Completed
- Sponsor
- YiChang HEC ChangJiang Pharmaceutical
- Start
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human insulin in diabetes mellitus type 1 (T1D), type 2 diabetes mellitus (T2DM), sponsored by YiChang HEC ChangJiang Pharmaceutical. Started Sep 2015; status: completed.
02
Drugs
human insulin
03
Conditions
diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20150293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150293.